Skip to content
BiologicalX

Comparison

Clomiphene vs Thymosin Alpha-1

Side-by-side of Clomiphene and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Clomiphene

  • SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
  • FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
  • Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
  • Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
  • Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
  • Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute Clomiphene Thymosin Alpha-1
Category pharmaceutical peptide
Also known as Clomid, clomiphene citrate, Serophene, enclomiphene Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 168 2
Typical dose (mg) 25 1.6
Dosing frequency 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label) 2x weekly
Routes oral subcutaneous, intramuscular
Onset (hr) 6 24
Peak (hr) 7 168
Molecular weight 405.96 3108.32
Molecular formula C26H28ClNO C129H215N33O55
Mechanism Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status Prescription only (FDA approved for ovulation induction; off-label in men) Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status banned unknown
DEA / Rx Rx only (not a controlled substance) Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Category X; contraindicated in pregnancy Not recommended; insufficient data
CAS 911-45-5 62304-98-7
PubChem CID 1548953 16130571
Wikidata Q416785 Q913854

Safety profile

Clomiphene

Common side effects

  • hot flushes
  • mood changes
  • abdominal discomfort
  • breast tenderness
  • visual disturbances (rare)
  • headache

Contraindications

  • pregnancy
  • active liver disease
  • ovarian cysts (not PCOS-related)
  • uncontrolled thyroid or adrenal disorder
  • abnormal uterine bleeding of undetermined origin
  • hormone-sensitive cancer

Interactions

  • tamoxifen: competing SERM activity; not used together(moderate)
  • ospemifene: competing SERM activity(moderate)
  • anastrozole: additive estrogen reduction; sometimes combined in male protocols(minor)
  • TRT (exogenous testosterone): TRT suppresses HPT axis that clomiphene targets; do not combine(moderate)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

Clomiphene and Thymosin Alpha-1 score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.

Edge case: If you cannot self-administer injections, Clomiphene is the only oral option in this pair.

Default choice: either is defensible. Clomiphene edges out on goal breadth + legal accessibility; Thymosin Alpha-1 is the right call if your priority sits in the goals listed above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Clomiphene and Thymosin Alpha-1?

Clomiphene and Thymosin Alpha-1 differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Clomiphene or Thymosin Alpha-1?

Clomiphene half-life is 168 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack Clomiphene with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper